CN104906554A - Traditional Chinese medicine composition for treating refractory gastroesophageal reflux disease and application thereof - Google Patents
Traditional Chinese medicine composition for treating refractory gastroesophageal reflux disease and application thereof Download PDFInfo
- Publication number
- CN104906554A CN104906554A CN201510418631.XA CN201510418631A CN104906554A CN 104906554 A CN104906554 A CN 104906554A CN 201510418631 A CN201510418631 A CN 201510418631A CN 104906554 A CN104906554 A CN 104906554A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- treatment
- rhizoma
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine composition for treating the refractory gastroesophageal reflux disease. The composition is produced through medicinal materials of inula stems, mangnolia officinalis, coptis, fructus evodiae, ginger, calcined flute, Chinese thorowax roots, corydalis tuber, rhizoma cyperi, stir-baked fructus gardenia, bitter orange, sealwort, radix paeoniae alba and liquorice. The invention further provides an application of the traditional Chinese medicine composition. The traditional Chinese medicine composition and the application have the advantages that the composition is used for treating the refractory gastroesophageal reflux disease, symptoms of substernal pains and discomfort, throat discomfort, heartburn, sour regurgitation, belching and the like are improved apparently, and the clinical efficacy rate is high.
Description
Technical field
The present invention relates to technical field of Chinese medicines, specifically, is a kind of Chinese medicine composition and application thereof for the treatment of refractory gastroesophageal reflux disease.
Background technology
Gastroesophageal reflux disease (gastroesophageal reflux disease, GERD) refers to that gastric content reflux food causes a kind of disease of malaise symptoms and (or) complication.Refractory gastroesophageal reflux disease refers to that gastroesophageal reflux disease (GERD) patient produces not exclusively for the PPI therapeutic scheme of standard dose or lacks response, and continuous exhibition is reflux symptom seriously and frequently.Current modern medicine still lacks effective method for the treatment of refractory gastroesophageal reflux disease, causes the attention of some scholars of disease for digest field, expert gradually, becomes a difficult problem urgently to be resolved hurrily.
Chinese patent application 201210262822.8 discloses a kind of medicine for the treatment of gastroesophageal reflux disease, is made up of following bulk drugs: Folium Eriobotryae, Radix Platycodonis, the Rhizoma Atractylodis Macrocephalae.Chinese patent literature 200710017349.6 discloses a kind of Chinese medicine composition for the treatment of gastroesophageal reflux disease, is made up of following crude drug: Radix Bupleuri, the Radix Paeoniae Alba, Fructus Aurantii, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens), Pericarpium Citri Reticulatae, Os Sepiae, Radix Scutellariae, Radix Curcumae, the Radix Aucklandiae, Radix Glycyrrhizae.Chinese patent application 200610147857.1 discloses a kind of Chinese medicine composition for the treatment of gastroesophageal reflux disease, is made up of following raw material: Flos Caryophylli, Haematitum, Radix Bupleuri, Fructus Aurantii, Rhizoma Coptidis, Fructus Evodiae, peninjau gardenia, Radix Pseudostellariae, Rhizoma Zingiberis Recens, Radix Glycyrrhizae, Rhizoma Corydalis, Fructus Toosendan, Myrrha (processed).Other patent documentation, technical paper, books etc. disclose the Chinese medicine composition of part treat gastroesophageal reflux disease, but yet there are no report about the Chinese medicine composition for the treatment of refractory gastroesophageal reflux disease of the present invention.
Summary of the invention
The object of the invention is for deficiency of the prior art, a kind of Chinese medicine composition for the treatment of refractory gastroesophageal reflux disease is provided.
Of the present invention again one object be that a kind of application for the treatment of the Chinese medicine composition of refractory gastroesophageal reflux disease is provided.
For achieving the above object, the technical scheme that the present invention takes is: a kind of Chinese medicine composition for the treatment of gastroesophageal reflux disease, and described Chinese medicine composition is made up of the crude drug of following weight portion: Flos Inulae obstructs 10-14 part, Cortex Magnoliae Officinalis 7-11 part, Rhizoma Coptidis 2-4 part, Fructus Evodiae 2-4 part, Rhizoma Zingiberis Recens 2-4 part, forges Concha Arcae 25-35 part, Radix Bupleuri 7-11 part, rhizoma corydalis 7-11 part, Rhizoma Cyperi 10-14 part, peninjau gardenia 7-11 part, Fructus Aurantii 20-14 part, Rhizoma Polygonati 13-17 part, Radix Paeoniae Alba 13-17 part, Radix Glycyrrhizae 4-8 part.
Described Chinese medicine composition is made up of the crude drug of following weight portion: Flos Inulae obstructs 11-13 part, Cortex Magnoliae Officinalis 8-10 part, Rhizoma Coptidis 2.5-3.5 part, Fructus Evodiae 2.5-3.5 part, Rhizoma Zingiberis Recens 2.5-3.5 part, forges Concha Arcae 28-32 part, Radix Bupleuri 8-10 part, rhizoma corydalis 8-10 part, Rhizoma Cyperi 11-13 part, peninjau gardenia 8-10 part, Fructus Aurantii 11-13 part, Rhizoma Polygonati 14-16 part, Radix Paeoniae Alba 14-16 part, Radix Glycyrrhizae 5-7 part.
Described Chinese medicine composition is made up of the crude drug of following weight portion: Flos Inulae obstructs 12 parts, Cortex Magnoliae Officinalis 9 parts, Rhizoma Coptidis 3 parts, Fructus Evodiae 3 parts, 3 parts, Rhizoma Zingiberis Recens, forges Concha Arcae 30 parts, Radix Bupleuri 9 parts, rhizoma corydalis 9 parts, Rhizoma Cyperi 12 parts, peninjau gardenia 9 parts, Fructus Aurantii 12 parts, Rhizoma Polygonati 15 parts, the Radix Paeoniae Alba 15 parts, 6 parts, Radix Glycyrrhizae.
For realizing above-mentioned second object, the technical scheme that the present invention takes is: the application of described Chinese medicine composition in the medicine of preparation treatment gastroesophageal reflux disease.
Described gastroesophageal reflux disease is refractory gastroesophageal reflux disease.
The invention has the advantages that:
1, Chinese medicine composition of the present invention has taken into account the feature relating to multisystem functional disorder of primary disease, Comprehensive Treatment anti-reflux barrier obstacle, esophagus clean up mechanism of damaged, reflux damage factor and Esophageal Mucosa defense factor unbalance, avoid PPI acid suppression treatment just the gastric acid in reflux thing, pepsin and the reflux damage factor relevant to sour environment are worked, and for " acid " dependency beyond damage factor effect limit to
2, Chinese medicine composition of the present invention is used for the treatment of refractory gastroesophageal reflux disease, and the symptom such as retrosternal pain discomfort, throat discomfort, heartburn, acid regurgitation, belch is improved significantly, and overall clinical efficacy rate is high.
Detailed description of the invention
Below in conjunction with embodiment, detailed description of the invention provided by the invention is elaborated.
The invention provides a kind of Chinese medicine composition for the treatment of refractory gastroesophageal reflux disease, described Chinese medicine composition is made up of the crude drug of following weight portion: Flos Inulae obstructs 10-14 part, Cortex Magnoliae Officinalis 7-11 part, Rhizoma Coptidis 2-4 part, Fructus Evodiae 2-4 part, Rhizoma Zingiberis Recens 2-4 part, forges Concha Arcae 25-35 part, Radix Bupleuri 7-11 part, rhizoma corydalis 7-11 part, Rhizoma Cyperi 10-14 part, peninjau gardenia 7-11 part, Fructus Aurantii 20-14 part, Rhizoma Polygonati 13-17 part, Radix Paeoniae Alba 13-17 part, Radix Glycyrrhizae 4-8 part.
Preferably, described Chinese medicine composition is made up of the crude drug of following weight portion: Flos Inulae obstructs 11-13 part, Cortex Magnoliae Officinalis 8-10 part, Rhizoma Coptidis 2.5-3.5 part, Fructus Evodiae 2.5-3.5 part, Rhizoma Zingiberis Recens 2.5-3.5 part, forges Concha Arcae 28-32 part, Radix Bupleuri 8-10 part, rhizoma corydalis 8-10 part, Rhizoma Cyperi 11-13 part, peninjau gardenia 8-10 part, Fructus Aurantii 11-13 part, Rhizoma Polygonati 14-16 part, Radix Paeoniae Alba 14-16 part, Radix Glycyrrhizae 5-7 part.
Embodiment 1 Chinese medicine composition
Flos Inulae obstructs 12 parts, Cortex Magnoliae Officinalis 9 parts, Rhizoma Coptidis 3 parts, Fructus Evodiae 3 parts, 3 parts, Rhizoma Zingiberis Recens, forges Concha Arcae 30 parts, Radix Bupleuri 9 parts, rhizoma corydalis 9 parts, Rhizoma Cyperi 12 parts, peninjau gardenia 9 parts, Fructus Aurantii 12 parts, Rhizoma Polygonati 15 parts, the Radix Paeoniae Alba 15 parts, 6 parts, Radix Glycyrrhizae
Embodiment 2 Chinese medicine composition
Flos Inulae obstructs 13 parts, Cortex Magnoliae Officinalis 8 parts, Rhizoma Coptidis 3.5 parts, Fructus Evodiae 2.5 parts, 3.5 parts, Rhizoma Zingiberis Recens, forges Concha Arcae 28 parts, Radix Bupleuri 10 parts, rhizoma corydalis 8 parts, Rhizoma Cyperi 13 parts, peninjau gardenia 8 parts, Fructus Aurantii 13 parts, Rhizoma Polygonati 14 parts, the Radix Paeoniae Alba 16 parts, 5 parts, Radix Glycyrrhizae
Embodiment 3 Chinese medicine composition
Flos Inulae obstructs 11 parts, Cortex Magnoliae Officinalis 10 parts, Rhizoma Coptidis 2.5 parts, Fructus Evodiae 3.5 parts, 2.5 parts, Rhizoma Zingiberis Recens, forges Concha Arcae 32 parts, Radix Bupleuri 8 parts, rhizoma corydalis 10 parts, Rhizoma Cyperi 11 parts, peninjau gardenia 10 parts, Fructus Aurantii 11 parts, Rhizoma Polygonati 16 parts, the Radix Paeoniae Alba 14 parts, 7 parts, Radix Glycyrrhizae
Embodiment 4 Chinese medicine composition
Flos Inulae obstructs 14 parts, Cortex Magnoliae Officinalis 7 parts, Rhizoma Coptidis 4 parts, Fructus Evodiae 2 parts, 4 parts, Rhizoma Zingiberis Recens, forges Concha Arcae 25 parts, Radix Bupleuri 11 parts, rhizoma corydalis 7 parts, Rhizoma Cyperi 14 parts, peninjau gardenia 7 parts, Fructus Aurantii 14 parts, Rhizoma Polygonati 13 parts, the Radix Paeoniae Alba 17 parts, 4 parts, Radix Glycyrrhizae
Embodiment 5 Chinese medicine composition
Flos Inulae obstructs 10 parts, Cortex Magnoliae Officinalis 11 parts, Rhizoma Coptidis 2 parts, Fructus Evodiae 4 parts, 2 parts, Rhizoma Zingiberis Recens, forges Concha Arcae 35 parts, Radix Bupleuri 7 parts, rhizoma corydalis 11 parts, Rhizoma Cyperi 10 parts, peninjau gardenia 11 parts, Fructus Aurantii 10 parts, Rhizoma Polygonati 17 parts, the Radix Paeoniae Alba 13 parts, 8 parts, Radix Glycyrrhizae
The preparation of embodiment 6 Chinese medicine composition
The pharmaceutical dosage form that the arbitrary described Chinese medicine composition of embodiment 1-5 is prepared by conventional formulation means, such as decoction, granule etc.
Embodiment 7 clinical trial
1 clinical data
1.1 object of study
Case 55 example is collected in this research altogether, all derives from April, 2009 to 2015 year Chinese and Western, Shanghai Univ. of Traditional Chinese Medicine in April attached Yueyang in conjunction with hospital's gastroesophageal reflux disease special outpatient clinic and ward case; All patients underwent's electronic gastroscopies, meet inclusive criteria; According to medical order random packet.
1.2 diagnostic criteria
1.2.1 GERD diagnostic criteria
Formulate with reference in October, 2006 " Chinese gastroesophageal reflux disease National Consensus ".
1.2.2 refractory gastroesophageal reflux disease diagnostic criteria
Meet the diagnostic criteria of above-mentioned GERD before treatment, the PPI (omeprazole 20mg, lansoprazole 30mg, pantoprazole 40mg, rabeprazole 20mg, esomeprazole is 40mg, is once a day) of standard dose, early 15-30min is oral before the meal.Treatment RE esophagitis sustainable existence after 8 weeks, and (or) gastroesophageal reflux disease diagnosis questionnaire symptom integral (GerdQ integration) >8 divides.
1.2.3 PPI treats successful criterion
Meet the diagnostic criteria of above-mentioned RE before treatment, the PPI of standard dose treats RE and fully recovers under esophagitis gastroscope after 8 weeks, and GerdQ<8 divides.
1.3 inclusive criteria
(1) meet above-mentioned diagnostic criteria;
(2) the age is between 18-80 year.
1.4 exclusion standard
(1) merge the one of following disease: peptic ulcer, stomach esophagus or operation on duodenum history, Zollinger-Eillison syndrome, primary esophageal power illness (as cardia achalasia, scleroderma, primary esophageal spasm), upper digestive tract malignant change, esophagitis medicamentosa disease, pyloric obstruction;
(2) Barrett esophagus, NERD, the RE irregular patient taken medicine in 8 weeks for the treatment of;
(3) conceived or women breast-feeding their children;
(4) there is language disorder;
(5) severe cardiovascular disease, hepatic and kidney function obstacle person.
1.5 reject standard
1. in this research use drug allergy or have serious adverse reaction and be not suitable with this clinical experiment person;
2. uncomplaisance or treatments period use other active drug person, or because a variety of causes does not complete the course for the treatment of or the infull person for the treatment of in treatment;
3. treatments period generation serious disease, can not proceed therapist;
4. the course for the treatment of is not to 1/2, is not counted in statistical result.
2 research methoies
For meet diagnostic criteria enter to organize patient, be divided into treatment group 28 example, matched group 27 example, give and treatment according to draft scheme.
2.1 Therapeutic Method
(1) treatment group and matched group all give identical Primary Care: raise the head of a bed, sleep before 3h no longer takes food, avoids food rich in fat, wine for giving off smoking, minimizing takes in the food (as chocolate, Herba Menthae, coffee, Bulbus Allii Cepae, Bulbus Allii etc.) that can reduce Lower esophageal ephincter (LES) pressure;
(2) treatment group adopts the Chinese medicine decoction of embodiment 1, and measure about 150ml, bid (decoction pieces is provided by Yueyang Chinese medicine pharmacy of the hospitals of traditional Chinese and western medicine), 0.5h takes after the meal, and observing time is 12 weeks;
(3) matched group gives rabeprazole (composite tablet pharmacy), 10mg, bid, within 15 minutes before the meal, takes, and mosapride (pharmacy of letter friendship) 5mg, tid, often within 15 minutes before the meal, take, observing time is 12 weeks.
2.2 observation index
(1) the change of cardinal symptom
The clinical symptoms table of integrals carries out classification according to the diagnostic criteria of Chinese gastroesophageal reflux disease National Consensus in 2006 and with reference to " new Chinese medicine guideline of clinical investigations " according to symptom weight: according to patient clinical symptom weight be divided into asymptomatic, light, in, heavy level Four: never there is this type of symptom in asymptomatic expression; Slight expression accidentally occurs, is less than every day once, does not affect work and rest; Moderate represents that every day occurrence frequency is between 1 time to 3 times; Severe represents that every day, occurrence frequency was greater than 3 times, affects work and rest, scores respectively with 0,1,2,3.
(2) clinical efficacy criterion
Recovery from illness: clinical symptom disappearance, symptom integral reduces >=95%.
Effective: clinical symptoms disappears substantially (having symptom to disappear very soon though even), and symptom integral reduces 70% ~ 94%.
Effective: clinical symptoms does not disappear, but alleviate than before, symptom integral reduces 30% ~ 69%.
Invalid: clinical symptoms does not disappear, degree does not alleviate, and symptom integral reduces < 30%.
Computing formula:
(3) lower esophageal mucosal inflammation degree criterion under gastroscope:
Recovery from illness: under scope, Esophageal Mucosa is normal;
Effective: under scope, Esophageal Mucosa inflammation does not disappear, Syndrome Scale reduces 2 grades;
Effective: under scope, Esophageal Mucosa inflammation end disappears, and Syndrome Scale reduces 1 grade;
Invalid: not reach above-mentioned standard person.
2.3 statistical method
Adopt Excel disposal data data, SPSS13.0 statistical analysis; Employing mean ± the standard deviation of measurement data Normal Distribution
describe, variance neat employing t check, and the employing of heterogeneity of variance corrects t and checks; Enumeration data adopts frequency and constituent ratio to describe, and statistical inference adopts χ
2inspection, ranked data adopt rank test, and P≤0.05 is for there being statistical significance all.
3 results of study
3.1 physical data
In this routine patient of research treatment group 28, the 1 routine course for the treatment of, not to 1/2, was not counted in statistical result; In the routine patient of matched group 27, the 4 routine courses for the treatment of, not to 1/2, were not counted in statistical result.
Treatment group 27 example, man 10 example, female 17 example; Matched group 23 example, man 8 example, women 15 example; Two groups of sex difference not statistically significants (P > 0.05).The oldest 75 years old for the treatment of group, minimum 31 years old, 56.73 ± 8.56 years old mean age; Matched group 23 example, the oldest 76 years old, minimum 32 years old, 56.65 ± 11.10 years old mean age, difference not statistically significant (P > 0.05) between group.The most elder of the treatment group course of disease 55 months, the shortest person 7 months, average course of disease 24.11 ± 15.68 months; The most elder of the matched group course of disease 54 months, the shortest person 8 months, average course of disease 24.52 ± 15.53 months; Compare no significant difference (P > 0.05) for two groups.Prompting has comparability.
3.2 clinical cardinal symptom integrations
(1) before and after two groups of treatments, heartburn symptom integral compares
Through rank test, before treatment, integration no significant difference (P > 0.05) between group, has comparability.Before and after treatment group treatment, symptom integral compares, and has significant difference (P < 0.05); Before and after treatment of control group, symptom integral is compared, no significant difference (P > 0.05); Before and after two groups of treatments, integration differential compares, and has significant difference (P < 0.05).Prompting treatment group obviously can improve the heartburn symptom of this group patient, and matched group is not obvious to this curative effect, and treatment group is better than matched group (see table 1).
Compare before and after the heartburn symptom integral treatment of table 1 liang group
Note: before treatment, vs matched group,
△p>0.05;
After treatment before vs treatment,
■p<0.05,
□p>0.05
Integration differential, vs matched group
★p<0.05
(2) before and after two groups of treatments, acid regurgitation symptom integral compares
Through rank test, before treatment, between group, integration no significant difference (P > 0.05) has comparability.Before and after treatment group treatment, symptom integral compares, and has significant difference (P < 0.05); Before and after treatment of control group, symptom integral compares, and has significant difference (P < 0.05); Before and after two groups of treatments, integration differential compares, and has significant difference (P < 0.05).Prompting treatment group and matched group all obviously can improve this group patient acid regurgitation symptom, and matched group is better than treatment group (see table 2).
Compare before and after table 2 liang group acid regurgitation symptom integral treatment
Note: before treatment, vs matched group,
△p>0.05
After treatment before vs treatment,
■p<0.05
Integration differential, vs matched group
★p<0.05
(3) before and after two groups of treatments, after breastbone, pain symptom integral compares
Through rank test, before treatment, integration no significant difference (P > 0.05) between group, has comparability.Before and after treatment group treatment, symptom integral compares, and has significant difference (P < 0.05); Before and after treatment of control group, symptom integral is compared, no significant difference (P > 0.05); Before and after two groups of treatments, integration differential compares, and has significant difference (P < 0.05).Prompting treatment group obviously can improve pain symptom after this group patient breastbone, and matched group is not obvious to this curative effect, and treatment group is better than matched group (see table 3).
Compare before and after the treatment of pain symptom integral after table 3 liang group breastbone
Note: before treatment, vs matched group,
△p>0.05
After treatment before vs treatment,
■p<0.05,
□p>0.05
Integration differential, vs matched group
★p<0.05
(4) before and after two groups of treatments, throat discomfort symptom integral compares
Through rank test, before treatment, integration no significant difference (P > 0.05) between group, has comparability.Before and after treatment group treatment, symptom integral compares, and has significant difference (P < 0.05); Before and after treatment of control group, symptom integral is compared, no significant difference (P > 0.05); Before and after two groups of treatments, integration differential compares, and has significant difference (P < 0.05).Prompting treatment group obviously can improve this group patient throat discomfort symptom, and matched group is not obvious to this curative effect, and treatment group is better than matched group (see table 4).
Compare before and after table 4 liang group throat discomfort symptom integral treatment
Note: before treatment, vs matched group,
△p>0.05
After treatment before vs treatment,
■p<0.05,
□p>0.05
Integration differential, vs matched group
★p<0.05
(5) before and after two groups of treatments, belch symptom integral compares
Through rank test, integration no significant difference (P > 0.05) between group before treatment, two groups have comparability.Before and after treatment group treatment, symptom integral compares, and has significant difference (P < 0.05); Before and after treatment of control group, symptom integral compares, and has significant difference (P < 0.05); Before and after two groups of treatments, integration differential compares, no significant difference (P > 0.05).Prompting treatment group, matched group all obviously can improve this group patient belch symptom, and therapeutic equivalence (see table 5).
Compare before and after table 5 liang group belch symptom integral treatment
Note: before treatment, vs matched group,
△p>0.05
After treatment before vs treatment,
■p<0.05
Integration differential, vs matched group
☆p>0.05
To there is number of cases in all the other symptoms less in this individuality studied, therefore do not give statistics.
3.3 clinical symptoms total mark situations of change
Treat front two groups of patients symptomatic's total marks to compare, no significant difference (P > 0.05), prompting has comparability.Before and after treatment group treatment, symptom total mark has significant difference (P < 0.05); Before and after treatment of control group, symptom total mark has significant difference (P < 0.05); Prompting treatment group and matched group all can improve the main clinic symptoms of this group patient.Treat forward and backward two groups of cardinal symptom total mark differences to compare, have significant difference (P < 0.05), point out and improving in this group patient clinical symptom, treatment group is better than matched group (see table 6).
Compare before and after table 6 liang group symptom total mark treatment
Note: vs matched group,
△p>0.05;
After treatment before vs treatment
▲p<0.01;
Front and back difference vs matched group
★p<0.05
Clinical symptoms therapeutic evaluation after 3.4 treatments
Clinical symptoms treats effective percentage: treatment group effective percentage is 74.07%, and matched group effective percentage is 47.83%, two groups and has compared significant difference (P < 0.05), and prompting treatment group is better than matched group (see table 7).
A table 7 liang group clinical symptoms effective percentage compares
Note: vs matched group,
▲p<0.05
The change of mucosal inflammation under 3.5 treatment front and back scopes
Some patients thinks that symptom is thoroughly alleviated and for gastroscopic fear, refuses the gastroscopy after 12 weeks.Participate in patient's totally 28 examples of gastroscope check, treatment group 16 example, LA classification situation: LA-A 13 example before treatment, LA-B 2 example, LA-C 1 example; LA classification situation: LA-A10 example before the treatment of matched group 12 example, LA-B 1 example, LA-C 1 example; Through fisher inspection, treat front two groups of patient's gastroscope classification constituent ratios no significant difference (P > 0.05), prompting has comparability.
Mucosal inflammation comparitive study under scope: treatment group stomach effective percentage is 68.75%, matched group effective percentage is 41.67% (see table 8).
Under table 8 scope, mucosal inflammation effective percentage compares
Note: vs matched group
△p>0.05
The above is only the preferred embodiment of the present invention; it should be pointed out that for those skilled in the art, under the prerequisite not departing from the inventive method; can also make some improvement and supplement, these improve and supplement and also should be considered as protection scope of the present invention.
Claims (5)
1. treat the Chinese medicine composition of gastroesophageal reflux disease for one kind, it is characterized in that, described Chinese medicine composition is made up of the crude drug of following weight portion: Flos Inulae obstructs 10-14 part, Cortex Magnoliae Officinalis 7-11 part, Rhizoma Coptidis 2-4 part, Fructus Evodiae 2-4 part, Rhizoma Zingiberis Recens 2-4 part, forges Concha Arcae 25-35 part, Radix Bupleuri 7-11 part, rhizoma corydalis 7-11 part, Rhizoma Cyperi 10-14 part, peninjau gardenia 7-11 part, Fructus Aurantii 20-14 part, Rhizoma Polygonati 13-17 part, Radix Paeoniae Alba 13-17 part, Radix Glycyrrhizae 4-8 part.
2. the Chinese medicine composition for the treatment of gastroesophageal reflux disease according to claim 1, it is characterized in that, described Chinese medicine composition is made up of the crude drug of following weight portion: Flos Inulae obstructs 11-13 part, Cortex Magnoliae Officinalis 8-10 part, Rhizoma Coptidis 2.5-3.5 part, Fructus Evodiae 2.5-3.5 part, Rhizoma Zingiberis Recens 2.5-3.5 part, forges Concha Arcae 28-32 part, Radix Bupleuri 8-10 part, rhizoma corydalis 8-10 part, Rhizoma Cyperi 11-13 part, peninjau gardenia 8-10 part, Fructus Aurantii 11-13 part, Rhizoma Polygonati 14-16 part, Radix Paeoniae Alba 14-16 part, Radix Glycyrrhizae 5-7 part.
3. the Chinese medicine composition for the treatment of gastroesophageal reflux disease according to claim 1, it is characterized in that, described Chinese medicine composition is made up of the crude drug of following weight portion: Flos Inulae obstructs 12 parts, Cortex Magnoliae Officinalis 9 parts, Rhizoma Coptidis 3 parts, Fructus Evodiae 3 parts, 3 parts, Rhizoma Zingiberis Recens, forges Concha Arcae 30 parts, Radix Bupleuri 9 parts, rhizoma corydalis 9 parts, Rhizoma Cyperi 12 parts, peninjau gardenia 9 parts, Fructus Aurantii 12 parts, Rhizoma Polygonati 15 parts, the Radix Paeoniae Alba 15 parts, 6 parts, Radix Glycyrrhizae.
4. according to the application of the arbitrary described Chinese medicine composition of claim 1-3 in the medicine of preparation treatment gastroesophageal reflux disease.
5. application according to claim 4, is characterized in that, described gastroesophageal reflux disease is refractory gastroesophageal reflux disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510418631.XA CN104906554B (en) | 2015-07-16 | 2015-07-16 | A kind of Chinese medicine composition for treating refractory gastroesophageal reflux disease and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510418631.XA CN104906554B (en) | 2015-07-16 | 2015-07-16 | A kind of Chinese medicine composition for treating refractory gastroesophageal reflux disease and its application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104906554A true CN104906554A (en) | 2015-09-16 |
| CN104906554B CN104906554B (en) | 2018-03-02 |
Family
ID=54076271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510418631.XA Active CN104906554B (en) | 2015-07-16 | 2015-07-16 | A kind of Chinese medicine composition for treating refractory gastroesophageal reflux disease and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104906554B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105213991A (en) * | 2015-10-23 | 2016-01-06 | 王丽媛 | Be used for the treatment of the Chinese medicine composition of gastroesophageal reflux disease |
| CN106039205A (en) * | 2016-06-14 | 2016-10-26 | 侯小霞 | Traditional Chinese medicine granules for treating reflux esophagitis and preparation method thereof |
| CN115282256A (en) * | 2022-09-16 | 2022-11-04 | 上海中医药大学附属岳阳中西医结合医院 | NERD disease and syndrome combination model and construction method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101209340A (en) * | 2006-12-25 | 2008-07-02 | 上海中医药大学附属岳阳中西医结合医院 | Chinese medicinal composition for treating gastroesophageal reflux disease |
| CN104306941A (en) * | 2014-10-30 | 2015-01-28 | 上海中医药大学附属岳阳中西医结合医院 | Medicament for treating non-erosive gastro-oesophageal reflux disease and application of medicament |
-
2015
- 2015-07-16 CN CN201510418631.XA patent/CN104906554B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101209340A (en) * | 2006-12-25 | 2008-07-02 | 上海中医药大学附属岳阳中西医结合医院 | Chinese medicinal composition for treating gastroesophageal reflux disease |
| CN104306941A (en) * | 2014-10-30 | 2015-01-28 | 上海中医药大学附属岳阳中西医结合医院 | Medicament for treating non-erosive gastro-oesophageal reflux disease and application of medicament |
Non-Patent Citations (2)
| Title |
|---|
| 余莉芳等: "《上海名老中医治疗消化病经验精粹》", 31 March 2007, 中国中医药出版社 * |
| 罗金燕等: "难治性胃食管反流病诊治进展", 《中国实用内科杂志》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105213991A (en) * | 2015-10-23 | 2016-01-06 | 王丽媛 | Be used for the treatment of the Chinese medicine composition of gastroesophageal reflux disease |
| CN105213991B (en) * | 2015-10-23 | 2020-06-12 | 王丽媛 | Traditional Chinese medicine composition for treating gastroesophageal reflux disease |
| CN106039205A (en) * | 2016-06-14 | 2016-10-26 | 侯小霞 | Traditional Chinese medicine granules for treating reflux esophagitis and preparation method thereof |
| CN115282256A (en) * | 2022-09-16 | 2022-11-04 | 上海中医药大学附属岳阳中西医结合医院 | NERD disease and syndrome combination model and construction method and application thereof |
| CN115282256B (en) * | 2022-09-16 | 2023-08-22 | 上海中医药大学附属岳阳中西医结合医院 | NERD disease and syndrome combination model and construction method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104906554B (en) | 2018-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100518810C (en) | Chinese medicinal composition for treating gastroesophageal reflux disease | |
| CN101391058A (en) | Preparation for clearing away the heat-evil and expelling superficial evils | |
| CN102274448B (en) | Pharmaceutical composition for treating spleen deficiency and qi stagnation type functional dyspepsia and preparation method | |
| CN102580019A (en) | Chinese medicinal composition for treating reflux esophagitis | |
| CN101732558A (en) | Traditional Chinese medicine granules used for treating chronic pharyngitis | |
| CN102205090B (en) | Chinese medicinal stagnancy-removing and stagnation-eliminating soup for treating liver depression qi stagnation type indigestion | |
| CN101209340B (en) | Chinese medicinal composition for treating gastroesophageal reflux disease | |
| CN103432545B (en) | A kind of medicine for pediatrics febricide and preparation method thereof | |
| CN104906554A (en) | Traditional Chinese medicine composition for treating refractory gastroesophageal reflux disease and application thereof | |
| CN101947293A (en) | Medicament for treating urinary tract infection and preparation method thereof | |
| CN106692784A (en) | Health-care medicated diet for large-intestine dampness-heat ulcerative colitis | |
| CN102813711B (en) | Medicine for treating gastroesophageal reflux disease and application of medicine | |
| CN104306941B (en) | A kind of medicine for treating Non-erosive gastroesophageal reflux disease and its application | |
| CN102302758B (en) | Pharmaceutical composition for treating functional dyspepsia (FD) based on intermingled cold and heat symptom and preparation method thereof | |
| CN101757602B (en) | Traditional Chinese medicine composition for treating cardiac carcinoma and preparation method thereof | |
| CN102861199A (en) | Traditional Chinese medicine composition for treating gastroesophageal reflux disease and preparation method | |
| CN101874888B (en) | Chinese medicinal composition for treating hiccup and preparation method thereof | |
| CN101732500A (en) | Medicine for preventing and treating acute and chronic pharyngitis and sphagitis | |
| CN101757601B (en) | Traditional Chinese medicine composite for treating esophageal rheumatism and preparation method thereof | |
| CN104784650A (en) | Pharmaceutical preparation for clinical nursing of gastric ulcer | |
| CN105396069A (en) | Preparation method for a traditional Chinese medicine composition used for treating chronic gastritis | |
| CN105213991A (en) | Be used for the treatment of the Chinese medicine composition of gastroesophageal reflux disease | |
| CN111298090A (en) | External use medicine liquid for treating gastrointestinal motility disorder disease | |
| CN100577199C (en) | Application of stomachic pill with cyperus and amomum | |
| CN102805795B (en) | Chinese medicinal composition for treating acute soft tissue injury of chest and hypochondrium and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |